LY
Lyell Immunopharma, Inc.
LYEL · NASDAQ
$11.01 +4.31% (+$0.46)
1M -29.10%
Market Cap $264.6M
P/E Ratio -
Div. Yield -
ROE 91.62%
Piotroski F-Score Weak
1/9Valuation
50 /100
Fair P/S 9,801.74x
P/B 1.13x
P/E N/A
Growth
0 /100
Declining Rev. growth 92.48%
Book val. growth 33.22%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 8,537.04%
Net margin 920,285.00%
Op. margin 711,330.00%
Quality
0 /100
Poor ROIC 70.80%
ROE 91.62%
ROA 79.86%
Debt
100 /100
Low Debt/Equity 0.16x
Current ratio 5.36x
Int. coverage N/A
Stability
21 /100
Unstable Beta -0.07x
Rev. volatility 31.09%
EPS volatility 630.98%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na LYEL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lynn Seely
Employees
161
Headquarters
South San Francisco
Nadcházející události
10 LIS
Earnings
Upcoming earnings report